Scrip Awards 2021
Sponsored by:
Sponsored by:
More from Clinical Trials
The biotech had been looking at options to survive since May.
Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.
Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.
Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.
More from R&D
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Join Andrew Warmington, Manufacturing Editor at Citeline, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics.
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system